Related Experiment Video
Updated: Aug 7, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma
Abstract:
The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) is linked to the presence of pancreatic cancer stem-like cells (CSCs) that respond poorly to current chemotherapy regimens. By small molecule compound screening targeting 142 epigenetic enzymes, we identified that bromodomain-containing protein BRD9, a component of the BAF histone remodelling complex, is a key chromatin regulator to orchestrate the stemness of pancreatic CSCs via cooperating with the TGFβ/Activin-SMAD2/3 signalling pathway. Inhibition and genetic ablation of BDR9 block the self-renewal, cell cycle entry into G0 phase and invasiveness of CSCs, and improve the sensitivity of CSCs to gemcitabine treatment. In addition, pharmacological inhibition of BRD9 significantly reduced the tumorigenesis in patient-derived xenografts mouse models and eliminated CSCs in tumours from pancreatic cancer patients. Mechanistically, inhibition of BRD9 disrupts enhancer-promoter looping and transcription of stemness genes in CSCs. Collectively, the data suggest BRD9 as a novel therapeutic target for PDAC treatment via modulation of CSC stemness.
Insights
Bromodomain-containing protein 9 (BRD9) regulates pancreatic cancer stem cell (CSC) stemness. Inhibiting BRD9 blocks CSC self-renewal and invasiveness, offering a new therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, partly due to chemotherapy-resistant cancer stem-like cells (CSCs).
- Identifying novel targets to overcome CSC-mediated resistance is crucial for improving PDAC treatment outcomes.
Approach:
- Conducted small molecule compound screening targeting 142 epigenetic enzymes to identify key regulators of pancreatic CSC stemness.
- Investigated the role of bromodomain-containing protein 9 (BRD9), a component of the BAF complex, in orchestrating CSC stemness.
- Utilized inhibition and genetic ablation of BRD9, alongside patient-derived xenografts (PDX) mouse models, to assess therapeutic potential.
Key Points:
- BRD9 inhibition and genetic ablation effectively block CSC self-renewal, cell cycle progression, and invasiveness.
- BRD9 targeting enhances CSC sensitivity to gemcitabine chemotherapy.
- Pharmacological inhibition of BRD9 significantly reduces PDAC tumorigenesis in vivo and eliminates CSCs in patient tumors.
- BRD9 inhibition disrupts enhancer-promoter looping and stemness gene transcription in CSCs.
Conclusions:
- BRD9 is a critical chromatin regulator of pancreatic CSC stemness, cooperating with the TGFβ/Activin-SMAD2/3 pathway.
- BRD9 represents a promising novel therapeutic target for PDAC, offering a strategy to modulate CSC stemness and overcome treatment resistance.
More Related Videos
Related Concept Videos
TGF - β Signaling Pathway
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Abnormal Proliferation
Canonical Wnt Signaling Pathway
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

